Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.43 USD
-0.07 (-4.35%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.43 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Fortress Biotech, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 81 | 178 | 306 | 233 | 137 |
Receivables | 15 | 28 | 24 | 20 | 14 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 10 | 14 | 10 | 1 | 1 |
Other Current Assets | 11 | 10 | 7 | 7 | 4 |
Total Current Assets | 117 | 230 | 346 | 262 | 156 |
Net Property & Equipment | 7 | 13 | 15 | 12 | 12 |
Investments & Advances | 0 | 0 | 0 | 18 | 11 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 20 | 27 | 13 | 15 | 7 |
Deposits & Other Assets | 7 | 4 | 3 | 3 | 18 |
Total Assets | 168 | 294 | 397 | 329 | 226 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 3 | 7 | 5 | 5 | 7 |
Accounts Payable | 74 | 97 | 91 | 41 | 35 |
Current Portion Long-Term Debt | 0 | 3 | 1 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1 | 1 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 17 | 3 | 0 | 1 |
Total Current Liabilities | 85 | 128 | 101 | 48 | 46 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 61 | 93 | 47 | 59 | 77 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 2 | 2 | 7 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 166 | 244 | 171 | 132 | 154 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 1 |
Capital Surplus | 717 | 676 | 656 | 583 | 462 |
Retained Earnings | -695 | -634 | -547 | -483 | -436 |
Other Equity | -21 | 8 | 117 | 97 | 46 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2 | 50 | 226 | 197 | 73 |
Total Liabilities & Shareholder's Equity | 168 | 294 | 397 | 329 | 226 |
Total Common Equity | 2 | 50 | 226 | 197 | 73 |
Shares Outstanding | 15.00 | 7.30 | 6.60 | 6.20 | 4.70 |
Book Value Per Share | 0.11 | 6.85 | 34.22 | 31.77 | 15.43 |
Fiscal Year End for Fortress Biotech, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 76 | 84 | 81 | 72 | 87 |
Receivables | 11 | 10 | 15 | 8 | 17 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 10 | 11 | 10 | 11 | 12 |
Other Current Assets | 7 | 12 | 11 | 6 | 12 |
Total Current Assets | 103 | 117 | 117 | 98 | 128 |
Net Property & Equipment | 4 | 6 | 7 | 7 | 7 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 19 | 19 | 20 | 21 | 22 |
Deposits & Other Assets | 5 | 6 | 7 | 7 | 6 |
Total Assets | 146 | 165 | 168 | 151 | 181 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 3 | 3 | 3 | 3 | 2 |
Accounts Payable | 69 | 76 | 74 | 81 | 99 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1 | 1 | 1 | 0 | 0 |
Other Current Liabilities | 0 | 5 | 5 | 10 | 25 |
Total Current Liabilities | 76 | 88 | 85 | 97 | 129 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 67 | 61 | 61 | 46 | 47 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 2 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 160 | 169 | 166 | 164 | 197 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 739 | 733 | 717 | 702 | 699 |
Retained Earnings | -721 | -710 | -695 | -686 | -681 |
Other Equity | -32 | -27 | -21 | -30 | -34 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -15 | -4 | 2 | -13 | -16 |
Total Liabilities & Shareholder's Equity | 146 | 165 | 168 | 151 | 181 |
Total Common Equity | -15 | -4 | 2 | -13 | -16 |
Shares Outstanding | 20.40 | 19.20 | 15.00 | 8.80 | 8.90 |
Book Value Per Share | -0.72 | -0.21 | 0.11 | -1.50 | -1.79 |